Cargando…

Complexity of progranulin mechanisms of action in mesothelioma

BACKGROUND: Mesothelioma is an aggressive disease with limited therapeutic options. The growth factor progranulin plays a critical role in several cancer models, where it regulates tumor initiation and progression. Recent data from our laboratories have demonstrated that progranulin and its receptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Ventura, Elisa, Xie, Christopher, Buraschi, Simone, Belfiore, Antonino, Iozzo, Renato V., Giordano, Antonio, Morrione, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720952/
https://www.ncbi.nlm.nih.gov/pubmed/36471440
http://dx.doi.org/10.1186/s13046-022-02546-4
_version_ 1784843659051532288
author Ventura, Elisa
Xie, Christopher
Buraschi, Simone
Belfiore, Antonino
Iozzo, Renato V.
Giordano, Antonio
Morrione, Andrea
author_facet Ventura, Elisa
Xie, Christopher
Buraschi, Simone
Belfiore, Antonino
Iozzo, Renato V.
Giordano, Antonio
Morrione, Andrea
author_sort Ventura, Elisa
collection PubMed
description BACKGROUND: Mesothelioma is an aggressive disease with limited therapeutic options. The growth factor progranulin plays a critical role in several cancer models, where it regulates tumor initiation and progression. Recent data from our laboratories have demonstrated that progranulin and its receptor, EphA2, constitute an oncogenic pathway in bladder cancer by promoting motility, invasion and in vivo tumor formation. Progranulin and EphA2 are expressed in mesothelioma cells but their mechanisms of action are not well defined. In addition, there are no data establishing whether the progranulin/EphA2 axis is tumorigenic for mesothelioma cells. METHODS: The expression of progranulin in various mesothelioma cell lines derived from all major mesothelioma subtypes was examined by western blots on cell lysates, conditioned media and ELISA assays. The biological roles of progranulin, EphA2, EGFR, RYK and FAK were assessed in vitro by immunoblots, human phospho-RTK antibody arrays, pharmacological (specific inhibitors) and genetic (siRNAs, shRNAs, CRISPR/Cas9) approaches, motility, invasion and adhesion assays. In vivo tumorigenesis was determined by xenograft models. Focal adhesion turnover was evaluated biochemically using focal adhesion assembly/disassembly assays and immunofluorescence analysis with focal adhesion-specific markers. RESULTS: In the present study we show that progranulin is upregulated in various mesothelioma cell lines covering all mesothelioma subtypes and is an important regulator of motility, invasion, adhesion and in vivo tumor formation. However, our results indicate that EphA2 is not the major functional receptor for progranulin in mesothelioma cells, where progranulin activates a complex signaling network including EGFR and RYK. We further characterized progranulin mechanisms of action and demonstrated that progranulin, by modulating FAK activity, regulates the kinetic of focal adhesion disassembly, a critical step for cell motility. CONCLUSION: Collectively, our results highlight the complexity of progranulin oncogenic signaling in mesothelioma, where progranulin modulate functional cross-talks between multiple RTKs, thereby suggesting the need for combinatorial therapeutic approaches to improve treatments of this aggressive disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-022-02546-4.
format Online
Article
Text
id pubmed-9720952
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97209522022-12-06 Complexity of progranulin mechanisms of action in mesothelioma Ventura, Elisa Xie, Christopher Buraschi, Simone Belfiore, Antonino Iozzo, Renato V. Giordano, Antonio Morrione, Andrea J Exp Clin Cancer Res Research BACKGROUND: Mesothelioma is an aggressive disease with limited therapeutic options. The growth factor progranulin plays a critical role in several cancer models, where it regulates tumor initiation and progression. Recent data from our laboratories have demonstrated that progranulin and its receptor, EphA2, constitute an oncogenic pathway in bladder cancer by promoting motility, invasion and in vivo tumor formation. Progranulin and EphA2 are expressed in mesothelioma cells but their mechanisms of action are not well defined. In addition, there are no data establishing whether the progranulin/EphA2 axis is tumorigenic for mesothelioma cells. METHODS: The expression of progranulin in various mesothelioma cell lines derived from all major mesothelioma subtypes was examined by western blots on cell lysates, conditioned media and ELISA assays. The biological roles of progranulin, EphA2, EGFR, RYK and FAK were assessed in vitro by immunoblots, human phospho-RTK antibody arrays, pharmacological (specific inhibitors) and genetic (siRNAs, shRNAs, CRISPR/Cas9) approaches, motility, invasion and adhesion assays. In vivo tumorigenesis was determined by xenograft models. Focal adhesion turnover was evaluated biochemically using focal adhesion assembly/disassembly assays and immunofluorescence analysis with focal adhesion-specific markers. RESULTS: In the present study we show that progranulin is upregulated in various mesothelioma cell lines covering all mesothelioma subtypes and is an important regulator of motility, invasion, adhesion and in vivo tumor formation. However, our results indicate that EphA2 is not the major functional receptor for progranulin in mesothelioma cells, where progranulin activates a complex signaling network including EGFR and RYK. We further characterized progranulin mechanisms of action and demonstrated that progranulin, by modulating FAK activity, regulates the kinetic of focal adhesion disassembly, a critical step for cell motility. CONCLUSION: Collectively, our results highlight the complexity of progranulin oncogenic signaling in mesothelioma, where progranulin modulate functional cross-talks between multiple RTKs, thereby suggesting the need for combinatorial therapeutic approaches to improve treatments of this aggressive disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-022-02546-4. BioMed Central 2022-12-05 /pmc/articles/PMC9720952/ /pubmed/36471440 http://dx.doi.org/10.1186/s13046-022-02546-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Ventura, Elisa
Xie, Christopher
Buraschi, Simone
Belfiore, Antonino
Iozzo, Renato V.
Giordano, Antonio
Morrione, Andrea
Complexity of progranulin mechanisms of action in mesothelioma
title Complexity of progranulin mechanisms of action in mesothelioma
title_full Complexity of progranulin mechanisms of action in mesothelioma
title_fullStr Complexity of progranulin mechanisms of action in mesothelioma
title_full_unstemmed Complexity of progranulin mechanisms of action in mesothelioma
title_short Complexity of progranulin mechanisms of action in mesothelioma
title_sort complexity of progranulin mechanisms of action in mesothelioma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720952/
https://www.ncbi.nlm.nih.gov/pubmed/36471440
http://dx.doi.org/10.1186/s13046-022-02546-4
work_keys_str_mv AT venturaelisa complexityofprogranulinmechanismsofactioninmesothelioma
AT xiechristopher complexityofprogranulinmechanismsofactioninmesothelioma
AT buraschisimone complexityofprogranulinmechanismsofactioninmesothelioma
AT belfioreantonino complexityofprogranulinmechanismsofactioninmesothelioma
AT iozzorenatov complexityofprogranulinmechanismsofactioninmesothelioma
AT giordanoantonio complexityofprogranulinmechanismsofactioninmesothelioma
AT morrioneandrea complexityofprogranulinmechanismsofactioninmesothelioma